DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling
DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling
复制标题
DAB2IP 通过 STAT3/Twist1/P-糖蛋白信号传导调节非肌层浸润性膀胱癌对吡柔比星的化疗耐药性和肿瘤复发。
DOI：
10.1016/j.cellsig.2015.09.014
复制
发表时间：
2015-12-01
影响因子：
4.8
通讯作者：
Fan, Jinhai
中科院分区：
文献类型：
--
作者：
Wu, Kaijie;Wang, Bin;Fan, Jinhai
There is a high frequency of tumor recurrence in non-muscle invasive bladder cancer (NMIBC) after transurethral resection and postoperative intravesical chemotherapy, however, the molecular mechanisms leading to the chemoresistance and tumor re-growth remain largely unknown. In this study, we observed a significant decrease of DAB2IP expression in high-grade and recurrent NMIBC specimens, which was negatively correlated with Twist1 expression and predicted a lower recurrence-free survival of patients. Mechanistically, DAB2IP could inhibit the phosphorylation and transactivation of STAT3, and then subsequently suppress the expression of Twist1 and its target gene P-glycoprotein, both of which were crucial for the pirarubicin chemoresistance and tumor re-growth of bladder cancer cells. Overall, this study reveals a new promising biomarker modulating the chemoresistance and tumor recurrence of NMIBC after bladder preservation surgery. (C) 2015 Elsevier Inc. All rights reserved.
